Navigation Links
Vitreoretinal Injection Cannula

ProductsVitreoretinal Injection Cannula
Company Bausch & Lomb Storz
Item Vitreoretinal Injection Cannula
Features 
Description 20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box.
Info Bausch & Lomb Storz
Customer Service: (585) 338-6000
Web site: http://www.storz.com/

Related medicine products :

1. Vitreoretinal Micro Cannula
2. Vitreoretinal Injection Cannula - Angled
3. Vitreoretinal Viscodissector
4. Vitreoretinal Micro Pick
5. BD Visitec Vitreoretinal Cannulas
6. Vitreoretinal Viscodissector 90 degrees
7. Vitreoretinal Viscodissector 45 degrees
8. Vitreoretinal Viscodissector 70 degrees
9. Micro Vitreoretinal Cannula Angled
10. Thallous Chloride Tl 201 Injection
11. 27 Gauge Air Injection Cannula
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
The Proteomeworks system is an integrated set of tools and technologies that enables protein function discovery. Innovative new tools for sample preparation, 2-D electrophoresis, staining, imaging an
...e range of concentration, temperature, ionic stren...ion than other methods. Its unique operating metho...ution of molecular weights, providing an efficient...elf-associating systems. The ProteomeLab XL-A/XL-I...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent.
Medicine Products:
(Date:5/16/2008)...,s Bed & Back; Merger Sets Up Healthy Back as...ain, LORTON, Va., May 16 /PRNewswire/ -- Healthy ...and workplace back wellness created an,ergonomic r...its rival,JoAnne,s Bed & Back. Healthy Back,s 18 ...s of $40million. JoAnne,s 16 mid-Atlantic stores,c...
(Date:5/16/2008)...wire-USNewswire/ -- This release is,being sent in ...on with the,National Cancer Institute, part of the...he American Society of Clinical,Oncology meeting i...ractice,in about 25 percent of patients with colon...he way colorectal cancers will be staged., * This...
(Date:5/16/2008)...s gain benefit from calcitriol, an oral form , ... activated vitamin D may cut the risk of death for...ease by about one quarter, a new study suggests. ...tients, those being treated with calcitriol, an or...risk of death lowered by 26 percent when compared ...
(Date:5/16/2008)...aise $38 Million for Life-threatening,Disease, BE...kers in nearly,every state will raise funds for cy...participating in GREAT STRIDES, the largest nation...announced today., May is National Cystic Fibrosis...ening genetic disease that causes fatal lung infec...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2
...an be tested in blood to indicate the possibility/.... A report in the 7th July 2005 issue of New E...d levels of Oxidized phospholipids may indicate th...have in their arteries of heart. This test may in ...
...is possible to improve the brain functions of schi...ion programs. Researchers from Washington Universi...trategies used by normal people to remember things...nts as much in remembering information. This proce...
...as found that people in their 50s with normal bloo...an those with hypertension or high blood pressure....pressure developed heart disease later in life tha... study has been published in the current issue of ...
...formation about the dish along with the food can m...d decisions. Student cafeterias can use cards to d...to help teenagers decide better. For most of the f... the nutritional information as more and more pack...
Other Medicine News:Health News:Normal Blood Pressure Could Add Over 5 Years To Your Life 2
(Date:5/16/2008)...swire-FirstCall/ -- Memory Pharmaceuticals,Corp. (...ral key development,programs at its R&D Day meetin...ted new clinical data for MEM 1414, its lead PDE4 ...ty in humans. In addition, the,Company has nominat...m its,5-HT6 antagonist program, and separately con...
(Date:5/16/2008)...wire/ -- BioVex Inc, a biotechnology,company devel...ctious,disease, announced today that the abstract ...linical trial of OncoVEX GM-CSF in advanced metast...iety of Clinical Oncology,(ASCO) website located a...,which describes the data as of the submission dat...
(Date:5/16/2008)...rkers -- for Lung Cancer Diagnosis and, Identifica...known Primary (CUP...ith High Sensitivity and, Specificity and Could ...esults of microRNA Signature to Identify Tissue Or...% and Specificity of 99%, REHOVOT, Israel and JER...
(Date:5/16/2008)...cally Significant Reductions in Selected ... be published in 2008 Proceedings of the American ...logy, SAN DIEGO, May 16 /-...unced today that, in a registrational bioequivalen...cally significant reduction,in general disorders a...
Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Poniard Pharmaceuticals Announces Upcoming Conference Participation 5030 1Poniard Pharmaceuticals Announces Upcoming Conference Participation 5030 2Thermo Fisher Scientific to Host Analyst Meeting 5025 1Thermo Fisher Scientific to Host Analyst Meeting 5025 2MedCath Corporation to Present at the Deutsche Bank Securities 33rd Annual Health Care Conference 18142 1United Therapeutics Reports First Quarter 2008 Financial Results 5024 1United Therapeutics Reports First Quarter 2008 Financial Results 5024 2United Therapeutics Reports First Quarter 2008 Financial Results 5024 3United Therapeutics Reports First Quarter 2008 Financial Results 5024 4United Therapeutics Reports First Quarter 2008 Financial Results 5024 5United Therapeutics Reports First Quarter 2008 Financial Results 5024 6United Therapeutics Reports First Quarter 2008 Financial Results 5024 7
...April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ...maceutical company focused on acquiring, developin...nnounced data from its,preclinical studies of VQD-... treatment of solid and hematologic tumors.,Pre-cl... 2007,Annual Meeting of the American Association f...
...e Top-Line Phase III Results for,Keppra® as Ad...diatric Patients from One Month to Less than Four ...- UCB today announced,positive top-line results fr...ntre, placebo-controlled study evaluating the,effi...m) (20-50,mg/kg/day) as adjunctive therapy in the ...
Other Medicine Technology:VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 2UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 3UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 4UCB Announces Positive Top-Line Phase III Results for Keppra as,Adjunctive Therapy for Partial Onset Seizures in Paediatric,Patients from One Month to Less than Four Years of Age 5